Efficacy and Safety of Alflutinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer Patients With T790M

NCT03452592 PHASE2 TERMINATED

This study is conducted to evaluate the efficacy and safety of Alflutinib in locally advanced or metastatic non-small cell lung cancer patients harbouring T790M mutation

Details

Lead sponsor	Allist Pharmaceuticals, Inc.
Phase	PHASE2
Status	TERMINATED
Enrolment	220
Start date	Mon Apr 30 2018 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Thu Mar 14 2024 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Advanced NSCLC Patients With T790M

Interventions

• Alflutinib

Countries

China